Close Menu

Natera

The company published a quality assurance study for the Panorama test last month and is wrapping up the SMART study, which has enrolled 20,000 women.

Divesting the cord blood business will allow Natera to focus on its genetic testing business in reproductive health, oncology, and organ transplantation.

The index, which slightly underperformed the Dow Jones, had a smaller loss in August than in the previous month.

A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.

The company is forging ahead with its Signatera liquid biopsy circulating tumor DNA minimal residual disease (MRD) test and Prospera transplant assessment assay.

The company beat analyst estimates on the top and bottom line, driven by sales of its Panorama noninvasive prenatal and Horizon carrier screening tests.

Individual stocks in the GenomeWeb Index were mostly down in May, with 21 of the 30 stocks posting losses and nine stocks recording gains.

The company's first quarter revenues were driven by sales of its noninvasive prenatal screening and carrier screening tests.

Two new studies of stage I to III CRC suggest that the presence of ctDNA in the months after surgery or chemotherapy can help identify patients who go on to relapse.

Pages

A new analysis finds that nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program influence patient care.

Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.

The owner of the GEDmatch website tells CBS12 he is considering charging law enforcement a fee to use the site.

In Nature this week: babies born by caesarean section are more likely to have altered gut microbiota profiles, and more.